Skip to main content
SpringerLink
Log in

Progressive Supranuclear Palsy

  • Chapter
Atypical Parkinsonian Disorders

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

Progressive supranuclear palsy (PSP) is the most common atypical neurodegenerative parkinsonian disorder (1,2). It was first described as a discrete clinicopathological entity by Steele et al. (3) in 1964 (Fig. 1), but there are several previous clinical descriptions of patients who may have had this disease (see Chapter 2). Clinically, PSP typically presents at middle-to-late age with progressive unexplained prominent postural instability with falls, supranuclear vertical gaze palsy, pseudobulbar palsy, levodopa-unresponsive parkinsonism, and frontal cognitive disturbances (3–5). Neuropathologically, PSP is characterized by the presence of neurofibrillary tangles in neurons and glia in specific basal ganglia and brainstem areas (6) (Fig.2). Neurofibrillary tangles are abnormal aggregates of tau protein that are also the main pathologic feature in corticobasal degeneration (CBD), Pick’s disease, frontotemporal dementia with parkinsonism associated to chromosome 17 abnormalities (FTDP-17), and Alzheimer’s disease (AD). Hence, as all these disorders, PSP is considered a “tauopathy” (see also Chapter 4).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 379.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997;49(5):1284–1288.

    PubMed  CAS  Google Scholar 

  2. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354(9192):1771–1775.

    Article  PubMed  CAS  Google Scholar 

  3. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. Arch Neurol 1964;10: 333–359.

    PubMed  CAS  Google Scholar 

  4. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47(1):1–9.

    PubMed  CAS  Google Scholar 

  5. Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56(12):1702–1706.

    PubMed  CAS  Google Scholar 

  6. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44(11): 2015–2019.

    PubMed  CAS  Google Scholar 

  7. Maher ER, Lees AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1986;36(7):1005–1008.

    PubMed  CAS  Google Scholar 

  8. Walsh JS, Welch HG, Larson EB. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med 1990;113(6):429–434.

    PubMed  CAS  Google Scholar 

  9. Tolosa E, Valldeoriola F, Marti MJ. Clinical diagnosis and diagnostic criteria of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). J Neural Transm Suppl 1994;42:15–31.

    PubMed  CAS  Google Scholar 

  10. Litvan I, Mangone CA, McKee A, Verny M, Parsa A, Jellinger K, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996;60(6):615–620.

    Article  PubMed  CAS  Google Scholar 

  11. Verny M, Jellinger KA, Hauw JJ, Bancher C, Litvan I, Agid Y. Progressive supranuclear palsy: a clinicopathological study of 21 cases. Acta Neuropathol 1996;91(4):427–431.

    Article  PubMed  CAS  Google Scholar 

  12. Santacruz P, Uttl B, Litvan I, Grafman J. Progressive supranuclear palsy: a survey of the disease course. Neurology 1998;50(6):1637–1647.

    PubMed  CAS  Google Scholar 

  13. Wenning GK, Ebersbach G, Verny M, Chaudhuri KR, Jellinger K, McKee A, et al. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord 1999;14(6):947–950.

    Article  PubMed  CAS  Google Scholar 

  14. Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ. Clinical features and natural history of progressive supranuclear palsy: A clinical cohort study. Neurology 2003;60(6):910–916.

    PubMed  CAS  Google Scholar 

  15. Litvan I, Grimes DA, Lang AE, Jankovic J, McKee A, Verny M, et al. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999; 246Suppl 2:II1–II5.

    Article  PubMed  Google Scholar 

  16. Litvan I, Campbell G, Mangone CA, Verny M, McKee A, Chaudhuri KR, et al. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain 1997;120(Pt 1):65–74.

    Article  PubMed  Google Scholar 

  17. Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry 1995;58(2):167–173.

    PubMed  CAS  Google Scholar 

  18. Barclay CL, Lang AE. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997; 62(4):352–356.

    PubMed  CAS  Google Scholar 

  19. Pillon B, Dubois B, Lhermitte F, Agid Y. Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson’s disease, and Alzheimer’s disease. Neurology 1986;36(9):1179–1185.

    PubMed  CAS  Google Scholar 

  20. Grafman J, Litvan I, Gomez C, Chase TN. Frontal lobe function in progressive supranuclear palsy. Arch Neurol 1990;47(5):553–558.

    PubMed  CAS  Google Scholar 

  21. Grafman J, Weingartner H, Newhouse PA, Thompson K, Lalonde F, Litvan I, et al. Implicit learning in patients with Alzheimer’s disease. Pharmacopsychiatry 1990;23(2):94–101.

    PubMed  CAS  Google Scholar 

  22. Pillon B, Dubois B, Ploska A, Agid Y. Severity and specificity of cognitive impairment in Alzheimer’s, Huntington’s, and Parkinson’s diseases and progressive supranuclear palsy. Neurology 1991; 41(5):634–643.

    PubMed  CAS  Google Scholar 

  23. Pillon B, Deweer B, Michon A, Malapani C, Agid Y, Dubois B. Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer’s, Parkinson’s, and Huntington’s diseases. Neurology 1994;44(7):1264–1270.

    PubMed  CAS  Google Scholar 

  24. Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996;47(5):1184–1189.

    PubMed  CAS  Google Scholar 

  25. Litvan I, Paulsen JS, Mega MS, Cummings JL. Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. Arch Neurol 1998;55(10):1313–1319.

    Article  PubMed  CAS  Google Scholar 

  26. Robbins TW, James M, Owen AM, Lange KW, Lees AJ, Leigh PN, et al. Cognitive deficits in progressive supranuclear palsy, Parkinson’s disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 1994;57(1):79–88.

    PubMed  CAS  Google Scholar 

  27. Verny M, Duyckaerts C, Agid Y, Hauw JJ. The significance of cortical pathology in progressive supranuclear palsy. Clinico-pathological data in 10 cases. Brain 1996;119(Pt 4):1123–1136.

    Article  PubMed  Google Scholar 

  28. Goetz CG, Leurgans S, Lang AE, Litvan I. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology 2003;60(6):917–922.

    PubMed  Google Scholar 

  29. Siderowf A, Quinn NP. Progressive supranuclear palsy: setting the scene for therapeutic trials. Neurology 2003;60(6):892–893.

    PubMed  Google Scholar 

  30. Lopez OL, Litvan I, Catt KE, Stowe R, Klunk W, Kaufer DI, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 1999;53(6):1292–1299.

    PubMed  CAS  Google Scholar 

  31. Davis PH, Bergeron C, McLachlan DR. Atypical presentation of progressive supranuclear palsy. Ann Neurol 1985;17(4):337–343.

    Article  PubMed  CAS  Google Scholar 

  32. Matsuo H, Takashima H, Kishikawa M, Kinoshita I, Mori M, Tsujihata M, et al. Pure akinesia: an atypical manifestation of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1991;54(5):397–400.

    PubMed  CAS  Google Scholar 

  33. Daniel SE, de Bruin VM, Lees AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain 1995;118(Pt 3):759–770.

    Article  PubMed  Google Scholar 

  34. Bergeron C, Pollanen MS, Weyer L, Lang AE. Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. J Neuropathol Exp Neurol 1997;56(6):726–734.

    PubMed  CAS  Google Scholar 

  35. Boeve B, Dickson D, Duffy J, Bartleson J, Trenerry M, Petersen R. Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology. Eur Neurol 2003; 49(2):72–78.

    Article  PubMed  CAS  Google Scholar 

  36. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology 1999;52(6):1214–1220.

    PubMed  CAS  Google Scholar 

  37. Mastaglia FL, Grainger K, Kee F, Sadka M, Lefroy R. Progressive supranuclear palsy (the Steele-Richarson-Olszewski syndrome) clinical and electrophysiological observations in eleven cases. Proc Aust Assoc Neurol 1973;10:35–44.

    PubMed  CAS  Google Scholar 

  38. Davis PH, Golbe LI, Duvoisin RC, Schoenberg BS. Risk factors for progressive supranuclear palsy. Neurology 1988;38(10):1546–1552.

    PubMed  CAS  Google Scholar 

  39. Nath U, Ben-Shlomo Y, Thomson RG, Morris HR, Wood NW, Lees AJ, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001;124(Pt 7):1438–1449.

    Article  PubMed  CAS  Google Scholar 

  40. Gilman S, Low P, Quinn N, Albanese A, Ben-Shlomo Y, Fowler C, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 1998; 8(6):359–362.

    Article  PubMed  CAS  Google Scholar 

  41. Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996;55(1):97–105.

    PubMed  CAS  Google Scholar 

  42. Mailliot C, Sergeant N, Bussiere T, Caillet-Boudin ML, Delacourte A, Buee L. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. FEBS Lett 1998;433(3): 201–204.

    Article  PubMed  CAS  Google Scholar 

  43. Buee L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick’s disease. Brain Pathol 1999;9(4):681–693.

    Article  PubMed  CAS  Google Scholar 

  44. Goedert M, Crowther RA, Spillantini MG. Tau mutations cause frontotemporal dementias. Neuron 1998; 21(5):955–958.

    Article  PubMed  CAS  Google Scholar 

  45. Sergeant N, Wattez A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively “exon 10” isoforms. J Neurochem 1999; 72(3):1243–1249.

    Article  PubMed  CAS  Google Scholar 

  46. Chambers CB, Lee JM, Troncoso JC, Reich S, Muma NA. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer’s disease. Ann Neurol 1999;46(3):325–332.

    Article  PubMed  CAS  Google Scholar 

  47. Ruberg M, Javoy-Agid F, Hirsch E, Scatton B, R LH, Hauw JJ, et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 1985;18(5):523–529.

    Article  PubMed  CAS  Google Scholar 

  48. Agid Y, Javoy-Agid F, Ruberg M, Pillon B, Dubois B, Duyckaerts C, et al. Progressive supranuclear palsy: anatomoclinical and biochemical considerations. Adv Neurol 1987;45:191–206.

    PubMed  CAS  Google Scholar 

  49. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci U S A 1987;84(16): 5976–5980.

    Article  PubMed  CAS  Google Scholar 

  50. Javoy-Agid F. Cholinergic and peptidergic systems in PSP. J Neural Transm Suppl 1994;42:205–218.

    PubMed  CAS  Google Scholar 

  51. Kasashima S, Oda Y. Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol (Berl) 2003;105(2):117–124.

    CAS  Google Scholar 

  52. Frattali CM, Grafman J, Patronas N, Makhlouf F, Litvan I. Language disturbances in corticobasal degeneration. Neurology 2000;54(4):990–992.

    PubMed  CAS  Google Scholar 

  53. Golbe L. Progressive supranuclear palsy in the molecular age. Lancet 2000;356:870–871.

    Article  PubMed  CAS  Google Scholar 

  54. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999;8(4):711–715.

    Article  PubMed  CAS  Google Scholar 

  55. Di Maria E, Tabaton M, Vigo T, Abbruzzese G, Bellone E, Donati C, et al. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol 2000;47(3):374–377.

    Article  PubMed  Google Scholar 

  56. D’Souza I, Poorkaj P, Hong M, Nochlin D, Lee VM, Bird TD, et al. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci USA 1999;96(10):5598–5603.

    Article  PubMed  CAS  Google Scholar 

  57. Iijima M, Tabira T, Poorkaj P, Schellenberg GD, Trojanowski JQ, Lee VM, et al. A distinct familial presenile dementia with a novel missense mutation in the tau gene. Neuroreport 1999;10(3):497–501.

    Article  PubMed  CAS  Google Scholar 

  58. Grover A, Houlden H, Baker M, Adamson J, Lewis J, Prihar G, et al. 5’ splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J Biol Chem 1999;274(21):15134–15143.

    Article  PubMed  CAS  Google Scholar 

  59. Bird TD, Nochlin D, Poorkaj P, Cherrier M, Kaye J, Payami H, et al. A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L). Brain 1999; 122(Pt 4):741–756.

    Article  PubMed  Google Scholar 

  60. Bugiani O, Murrell JR, Giaccone G, Hasegawa M, Ghigo G, Tabaton M, et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 1999;58(6): 667–677.

    PubMed  CAS  Google Scholar 

  61. van Swieten JC, Stevens M, Rosso SM, Rizzu P, Joosse M, de Koning I, et al. Phenotypic variation in hereditary frontotemporal dementia with tau mutations. Ann Neurol 1999;46(4):617–626.

    Article  PubMed  Google Scholar 

  62. Rojo A, Pernaute RS, Fontan A, Ruiz PG, Honnorat J, Lynch T, et al. Clinical genetics of familial progressive supranuclear palsy. Brain 1999;122(Pt 7):1233–1245.

    Article  PubMed  Google Scholar 

  63. Morris HR, Katzenschlager R, Janssen JC, Brown JM, Ozansoy M, Quinn N, et al. Sequence analysis of tau in familial and sporadic progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2002;72(3):388–390.

    Article  PubMed  CAS  Google Scholar 

  64. Swerdlow RH, Golbe LI, Parks JK, Cassarino DS, Binder DR, Grawey AE, et al. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J Neurochem 2000; 75(4):1681–1684.

    Article  PubMed  CAS  Google Scholar 

  65. Albers DS, Beal MF. Mitochondrial dysfunction in progressive supranuclear palsy. Neurochem Int 2002; 40(6):559–564.

    Article  PubMed  CAS  Google Scholar 

  66. Di Monte DA, Harati Y, Jankovic J, Sandy MS, Jewell SA, Langston JW. Muscle mitochondrial ATP production in progressive supranuclear palsy. J Neurochem 1994;62(4):1631–1634.

    Article  PubMed  Google Scholar 

  67. Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson’s disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson’s Disease Research Group. Ann Neurol 1992;32(Suppl):S82–S87.

    Article  PubMed  CAS  Google Scholar 

  68. Jenner P. Oxidative stress in Parkinson’s disease and other neurodegenerative disorders. Pathol Biol (Paris) 1996;44(1):57–64.

    CAS  Google Scholar 

  69. Albers DS, Augood SJ, Martin DM, Standaert DG, Vonsattel JP, Beal MF. Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy. J Neurochem 1999;73(2):881–884.

    Article  PubMed  CAS  Google Scholar 

  70. Albers DS, Augood SJ, Park LC, Browne SE, Martin DM, Adamson J, et al. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J Neurochem 2000; 74(2):878–881.

    Article  PubMed  CAS  Google Scholar 

  71. Odetti P, Garibaldi S, Norese R, Angelini G, Marinelli L, Valentini S, et al. Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropathol Exp Neurol 2000;59(5):393–397.

    PubMed  CAS  Google Scholar 

  72. Ferrer I, Blanco R, Carmona M, Puig B. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm 2001;108(12):1397–1415.

    Article  PubMed  CAS  Google Scholar 

  73. Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, et al. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick’s disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 2001;11(2):144–158.

    Article  PubMed  CAS  Google Scholar 

  74. Drache B, Diehl GE, Beyreuther K, Perlmutter LS, Konig G. Bcl-xl-specific antibody labels activated microglia associated with Alzheimer’s disease and other pathological states. J Neurosci Res 1997;47(1): 98–108.

    Article  PubMed  CAS  Google Scholar 

  75. Lippa CF, Flanders KC, Kim ES, Croul S. TGF-beta receptors-I and-II immunoexpression in Alzheimer’s disease: a comparison with aging and progressive supranuclear palsy. Neurobiol Aging 1998;19(6): 527–533.

    Article  PubMed  CAS  Google Scholar 

  76. Lippa CF, Smith TW, Flanders KC. Transforming growth factor-beta: neuronal and glial expression in CNS degenerative diseases. Neurodegeneration 1995;4(4):425–432.

    Article  PubMed  CAS  Google Scholar 

  77. Uchihara T, Mitani K, Mori H, Kondo H, Yamada M, Ikeda K. Abnormal cytoskeletal pathology peculiar to corticobasal degeneration is different from that of Alzheimer’s disease or progressive supranuclear palsy. Acta Neuropathol (Berl) 1994;88(4):379–383.

    Article  CAS  Google Scholar 

  78. McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease. Neurology 1992;42(2):447–449.

    PubMed  CAS  Google Scholar 

  79. Halliday G, Robinson SR, Shepherd C, Kril J. Alzheimer’s disease and inflammation: a review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol 2000;27(1–2):1–8.

    Article  PubMed  CAS  Google Scholar 

  80. Mackenzie IR. Anti-inflammatory drugs and Alzheimer-type pathology in aging. Neurology 2000;54(3): 732–734.

    PubMed  CAS  Google Scholar 

  81. Arima K, Murayama S, Oyanagi S, Akashi T, Inose T. Presenile dementia with progressive supranuclear palsy tangles and Pick bodies: an unusual degenerative disorder involving the cerebral cortex, cerebral nuclei, and brain stem nuclei. Acta Neuropathol (Berl) 1992;84(2):128–134.

    Article  CAS  Google Scholar 

  82. Imran MB, Kawashima R, Awata S, Sato K, Kinomura S, Ono S, et al. Parametric mapping of cerebral blood flow deficits in Alzheimer’s disease: a SPECT study using HMPAO and image standardization technique. J Nucl Med 1999;40(2):244–249.

    PubMed  CAS  Google Scholar 

  83. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology 1996;47(2):425–432.

    PubMed  CAS  Google Scholar 

  84. Golbe LI, Rubin RS, Cody RP, Belsh JM, Duvoisin RC, Grosmann C, et al. Follow-up study of risk factors in progressive supranuclear palsy. Neurology 1996;47(1):148–154.

    PubMed  CAS  Google Scholar 

  85. Caparros-Lefebvre D, Sergeant N, Lees A, Camuzat A, Daniel S, Lannuzel A, et al. Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain 2002;125(Pt 4):801–811.

    Article  PubMed  Google Scholar 

  86. Caparros-Lefebvre D, Elbaz A. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group. Lancet 1999; 354(9175):281–286.

    Article  PubMed  CAS  Google Scholar 

  87. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995;274(1):329–336.

    PubMed  CAS  Google Scholar 

  88. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Munoz-Patino AM, Labandeira-Garcia JL. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson’s disease. J Neurochem 2000;74(4):1605–1612.

    Article  PubMed  CAS  Google Scholar 

  89. Kotake Y, Tasaki Y, Makino Yea. 1-Benzyl-1,2,3,4-Tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J Neurochem 1995;65:2633–2638.

    Article  PubMed  CAS  Google Scholar 

  90. Kawai H, Makino Y, Hirobe M, Ohta S. Novel Endogenous 1,2,3,4-tetrahydroisoquinoline derivative: uptake by dopamine transporter and activity to induce parkinsonism. J Neurochem 1998;70:745–751.

    Article  PubMed  CAS  Google Scholar 

  91. Tasaki Y, Makino Y, Ohta S, Hirobe M. 1-Methyl-1,2,3,4-tetrahydroisoquioline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonims-like behavior abnormalities. J Neurochemi 1991;57:1940–1943.

    Article  CAS  Google Scholar 

  92. Kotake T, Yoshida M, Ogawa Mea. Chronic Administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate. Neuroscience Letters 1996;217:69–71.

    Article  PubMed  CAS  Google Scholar 

  93. Nagatsu T, Yoshida M. An edogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci Lett. 1988;87:178–182.

    Article  PubMed  CAS  Google Scholar 

  94. Yoshida M, Niwa T, Nagatsu T. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinolone: the behavioral and biochemical changes. Neuroscie Lett. 1990; 119:109–113.

    Article  CAS  Google Scholar 

  95. Lannuzel A, Michel PP, Abaul MJ, Caparros-Lefebvre D, Ruberg M. Neurotoxic effects of alkaloids from Annona muricata (sour-sop) on dopaminergic neurons: potential role in etiology of atypical parkinsonism in French West Indies. Mov Disord 2000;13(Suppl 3):28 [Abstract].

    Google Scholar 

  96. Friedrich MJ. Pesticide study aids Parkinson research. JAMA 1999;282:2200.

    Article  PubMed  CAS  Google Scholar 

  97. Makino Y, Ohta S, Tachikawa O, Hirobe M. Presence of Tetrahydroisoquinoline and 1-Methyl-Tetrahydro-Isoquinoline in Foods: Compounds Related to Parkinson’s Disease. Life Sciences 1988; 43:373–378.

    Article  PubMed  CAS  Google Scholar 

  98. Niwa T, Takeda N, Sasaoka T, Kaneda T, hashizume Y, Yoshizumi H, Tatematsu A, et al. Detection of tetrahydroisoquinoline in parkinsonian brain as an endogenous amine by use of gas chromatography-mass spectrometry. J Chromatogr 1989;491:397–403.

    Article  PubMed  CAS  Google Scholar 

  99. Spencer PS, Kisby GE, Ross SM, Roy DN, Hugon J, Ludolph AC, et al. Guam ALS-PDC: possible causes. Science 1993;262(5135):825–826.

    Article  PubMed  CAS  Google Scholar 

  100. Zhang ZX, Anderson DW, Mantel N, Roman GC. Motor neuron disease on Guam: geographic and familial occurrence, 1956–85. Acta Neurol Scand 1996;94(1):51–59.

    PubMed  CAS  Google Scholar 

  101. Zhang ZX, Anderson DW, Mantel N. Geographic patterns of parkinsonism-dementia complex on Guam, 1956 through 1985. Arch Neurol 1990;47(10):1069–1074.

    PubMed  CAS  Google Scholar 

  102. McCrank E. PSP risk factors. Neurology 1990;40(10):1637.

    PubMed  CAS  Google Scholar 

  103. McCrank E, Rabheru K. Four cases of progressive supranuclear palsy in patients exposed to organic solvents. Can J Psychiatry 1989;34(9):934–936.

    PubMed  CAS  Google Scholar 

  104. Tetrud J, Langston J, Irwin I, Snow B. Parkinsonism caused by petroleum waste ingestion. Neurology 1994;44: 1051–1054.

    PubMed  CAS  Google Scholar 

  105. Pezzoli G, Ricciardi S, Masotto C, Mariani CB, Carenzi A. n-Hexane induces parkinsonism in rodents. Brain Res 1990;531(1–2):355–357.

    Article  PubMed  CAS  Google Scholar 

  106. Pezzoli G, Barbieri S, Ferrante C, Zecchinelli A, Foa V. Parkinsonism due to n-hexane exposure [letter]. Lancet 1989;2(8667):874.

    Article  PubMed  CAS  Google Scholar 

  107. Geddes JF, Vowles GH, Nicoll JA, Revesz T. Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol (Berl) 1999;98:171–178.

    Article  CAS  Google Scholar 

  108. Bhatt M, Desai J, Mankodi A, Elias M, Wadia N. Posttraumatic akinetic-rigid syndrome resembling Parkinson’s disease: a report on three patients. Mov Disord 2000;15(2):313–317.

    Article  PubMed  CAS  Google Scholar 

  109. Goetz CG, Pappert EJ. Trauma and movement disorders. Neurol Clin 1992;10(4):907–919.

    PubMed  CAS  Google Scholar 

  110. Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999;53(6):1284–1291.

    PubMed  CAS  Google Scholar 

  111. O’Meara ES, Kukull WA, Sheppard L, Bowen JD, McCormick WC, Teri L, et al. Head injury and risk of Alzheimer’s disease by apolipoprotein E genotype. Am J Epidemiol 1997;146:373–384.

    PubMed  CAS  Google Scholar 

  112. Nemetz PN, Leibson C, Naessens JM, Beard M, Kokmen E, Annegers JF, et al. Traumatic brain injury and time to onset of Alzheimer’s disease: a population-based study. Am J Epidemiol 1999;149:32–40.

    PubMed  CAS  Google Scholar 

  113. Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H, et al. Head injury and the risk of AD in the MIRAGE study. Neurology 2000;54:1316–1323.

    PubMed  CAS  Google Scholar 

  114. Kofler M, Muller J, Wenning GK, Reggiani L, Hollosi P, Bosch S, et al. The auditory startle reaction in parkinsonian disorders. Mov Disord 2001;16(1):62–71.

    Article  PubMed  CAS  Google Scholar 

  115. Mehta KM, Ott A, Kalmijn S, Slooter AJ, vanDuijn CM, Hofman A, et al. Head trauma and risk of dementia and Alzheimer’s disease: the Rotterdam Study. Neurology 1999;53:1959–1962.

    PubMed  CAS  Google Scholar 

  116. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, et al. Rates and risk factors for dementia and Alzheimer’s disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 1999;52:78–84.

    PubMed  CAS  Google Scholar 

  117. Luukinen H, Viramo P, Koski K, Laippala P, Kivela SL. Head injuries and cognitive decline among older adults—a population-based study. Neurology 1999;52:557–562.

    PubMed  CAS  Google Scholar 

  118. Vanacore N, Bonifati V, Fabbrini G, Colosimo C, Marconi R, Nicholl D, et al. Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology 2000; 54(1):114–119.

    PubMed  CAS  Google Scholar 

  119. Fujii C, Harado S, Ohkoshi N, Hayashi A, Yoshizawa K. Cross-cultural traits for personality of patients with Parkinson’s disease in Japan. Am J Med Genet 2000;96:1–3.

    Article  PubMed  CAS  Google Scholar 

  120. Nefzger M, Quadfasel F, Karl V. A retrospective study of smoking in parkinson’s disease. Am J Epidemiol 1968;88:149–158.

    PubMed  CAS  Google Scholar 

  121. Morens D, Grandinetti A, Reed D, White L, Ross G. Cigarette smoking and protection from Parkinson’s disease: false association or etiologic clue? Neurology 1995;45:1041–1051.

    PubMed  CAS  Google Scholar 

  122. Dubinsky RM, Jankovic J. Progressive supranuclear palsy and a multi-infarct state. Neurology 1987; 37(4):570–576.

    PubMed  CAS  Google Scholar 

  123. Winikates J, Jankovic J. Vascular progressive supranuclear palsy. J Neural Transm Suppl 1994;42: 189–201.

    PubMed  CAS  Google Scholar 

  124. Gearing M, Olson DA, Watts RL, Mirra SS. Progressive supranuclear palsy: neuropathologic and clinical heterogeneity. Neurology 1994;44(6):1015–1024.

    PubMed  CAS  Google Scholar 

  125. Fabbrini G, Vanacore N, Bonifati V, Colosimo C, Meco G. Presymptomatic hypertension in progressive supranuclear palsy. Study Group on Atypical Parkinsonisms [letter]. Arch Neurol 1998;55(8):1153–1155.

    Article  PubMed  CAS  Google Scholar 

  126. Ghika J, Bogousslavsky J. Presymptomatic hypertension is a major feature in the diagnosis of progressive supranuclear palsy. Arch Neurol 1997;54(9):1104–1108.

    PubMed  CAS  Google Scholar 

  127. Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996;46(4): 922–930.

    PubMed  CAS  Google Scholar 

  128. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003;54(Suppl 5):S15–S19.

    Article  PubMed  Google Scholar 

  129. Boeve BF, Maraganore DM, Parisi JE, Ivnik RJ, Westmoreland BF, Dickson DW, et al. Corticobasal degeneration and frontotemporal dementia presentations in a kindred with nonspecific histopathology. Dement Geriatr Cogn Disord 2002;13(2):80–90.

    Article  PubMed  CAS  Google Scholar 

  130. Vidailhet M, Rivaud S, Gouider-Khouja N, Pillon B, Bonnet AM, Gaymard B, et al. Eye movements in parkinsonian syndromes. Ann Neurol 1994;35(4):420–426.

    Article  PubMed  CAS  Google Scholar 

  131. Rivaud-Pechoux S, Vidailhet M, Gallouedec G, Litvan I, Gaymard B, Pierrot-Deseilligny C. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology 2000;54(5): 1029–1032.

    PubMed  CAS  Google Scholar 

  132. Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000;54(3):697–702.

    PubMed  CAS  Google Scholar 

  133. Yekhlef F, Ballan G, Macia F, Delmer O, Sourgen C, Tison F. Routine MRI for the differential diagnosis of Parkinson’s disease, MSA, PSP, and CBD. J Neural Transm 2003;110(2):151–169.

    Article  PubMed  CAS  Google Scholar 

  134. Savoiardo M. Differential diagnosis of Parkinson’s disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci 2003;24(Suppl 1):S35–S37.

    Article  PubMed  Google Scholar 

  135. Warmuth-Metz M, Naumann M, Csoti I, Solymosi L. Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch Neurol 2001;58(7):1076–1079.

    Article  PubMed  CAS  Google Scholar 

  136. Pillon B, Dubois B, Agid Y. Testing cognition may contribute to the diagnosis of movement disorders. Neurology 1996;46:329–334.

    Article  PubMed  CAS  Google Scholar 

  137. Johnson R, Jr., Litvan I, Grafman J. Progressive supranuclear palsy: altered sensory processing leads to degraded cognition. Neurology 1991;41(8):1257–1262.

    PubMed  Google Scholar 

  138. Takeda M, Tachibana H, Okuda B, Kawabata K, Sugita M. Electrophysiological comparison between corticobasal degeneration and progressive supranuclear palsy. Clin Neurol Neurosurg 1998;100(2):94–98.

    Article  PubMed  CAS  Google Scholar 

  139. Okuda B, Tachibana H, Takeda M, Kawabata K, Sugita M. Asymmetric changes in somatosensory evoked potentials correlate with limb apraxia in corticobasal degeneration. Acta Neurol Scand 1998;97(6):409–412.

    Article  PubMed  CAS  Google Scholar 

  140. Valls-Sole J. Neurophysiological characterization of parkinsonian syndromes. Neurophysiol Clin 2000; 30(6):352–367.

    Article  PubMed  CAS  Google Scholar 

  141. Valldeoriola F, Valls-Sole J, Tolosa ES, Marti MJ. Striated anal sphincter denervation in patients with progressive supranuclear palsy. Mov Disord 1995;10(5):550–555.

    Article  PubMed  CAS  Google Scholar 

  142. Litvan I, Blesa R, Clark K, Nichelli P, Atack JR, Mouradian MM, et al. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann Neurol 1994;36(1):55–61.

    Article  PubMed  CAS  Google Scholar 

  143. Kompoliti K, Goetz CG, Litvan I, Jellinger K, Verny M. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998;55(8):1099–1102.

    Article  PubMed  CAS  Google Scholar 

  144. Weiner WJ, Minagar A, Shulman LM. Pramipexole in progressive supranuclear palsy. Neurology 1999; 52(4):873–874.

    PubMed  CAS  Google Scholar 

  145. Litvan I, Gomez C, Atack JR, Gillespie M, Kask AM, Mouradian MM, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol 1989;26(3):404–407.

    Article  PubMed  CAS  Google Scholar 

  146. Foster NL, Aldrich MS, Bluemlein L, White RF, Berent S. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 1989;39(2 Pt 1):257–261.

    PubMed  CAS  Google Scholar 

  147. Frattali CM, Sonies BC, Chi-Fishman G, Litvan I. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: a pilot study. Dysphagia 1999;14(3):165–168.

    Article  PubMed  CAS  Google Scholar 

  148. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 2001;57(3):467–473.

    PubMed  CAS  Google Scholar 

  149. Pascual J, Berciano J, Gonzalez AM, Grijalba B, Figols J, Pazos A. Autoradiographic demonstration of loss of alpha 2-adrenoceptors in progressive supranuclear palsy: preliminary report. J Neurol Sci 1993;114(2): 165–169.

    Article  PubMed  CAS  Google Scholar 

  150. Ghika J, Tennis M, Hoffman E, Schoenfeld D, Growdon J. Idazoxan treatment in progressive supranuclear palsy. Neurology 1991;41(7):986–991.

    PubMed  CAS  Google Scholar 

  151. Rascol O, Sieradzan K, Peyro-Saint-Paul H, Thalamas C, Brefel-Courbon C, Senard JM, et al. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Mov Disord 1998;13(4):673–676.

    Article  PubMed  CAS  Google Scholar 

  152. Litvan I, Dickson DW, Buttner-Ennever JA, Delacourte A, Hutton M, Dubois B, et al. Research goals in progressive supranuclear palsy. First International Brainstorming Conference on PSP. Mov Disord 2000;15(3): 446–458.

    Article  PubMed  CAS  Google Scholar 

  153. Steele JC. Introduction. In: Litvan I, Agid A, eds. Progressive Supranuclear Palsy: Clinical and Research Aspects. New York: Oxford University Press, 1992:3–14.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, KY

    Irene Litvan MD (Raymond Lee Lebby Professor of Parkinson Disease Research, Director)

Authors
  1. Irene Litvan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Movement Disorder Program, Department of Neurology, University of Louisville School of Medicine, Louisville, KY

    Irene Litvan MD (Raymond Lee Lebby Professor of Parkinson Disease Research, Director) (Raymond Lee Lebby Professor of Parkinson Disease Research, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Litvan, I. (2005). Progressive Supranuclear Palsy. In: Litvan, I. (eds) Atypical Parkinsonian Disorders. Current Clinical Neurology. Humana Press. https://doi.org/10.1385/1-59259-834-X:287

Download citation

  • DOI: https://doi.org/10.1385/1-59259-834-X:287

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-331-2

  • Online ISBN: 978-1-59259-834-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation